ASH 2023 | Personalizing AML treatment by targeting MRD mutations
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks on the monitoring of measurable residual disease (MRD) to personalize treatment for patients with acute myeloid leukemia (AML). He highlights the potential for targeting specific mutations with FLT3 inhibitors, venetoclax targeting NPM1 mutations, and IDH inhibitors but recognizes this may become difficult if there are multiple mutations present. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: FujiFilm, Astellas Global Pharma
Consultancy: Takeda, Menarini, Jazz, Daiichi-Sankyo, Bristol Myers Squibb, Amgen, Abbvie, Pfizer
